Despite the improvement in clinical outcomes for head and neck squamous cell carcinoma (HNSCC) as the result of cetuximab, patients may present with or develop resistance that increases tumor recurrence rates and limits clinical efficacy. Therefore, identifying those patients who are or become resistant is essential to tailor the best therapeutic approach.
Materials and Methods:
Cetuximab was conjugated to p-NCS-Bz-DFO and labeled with 89Zr. The resistance model was developed by treating FaDu cells with cetuximab. Western blotting (WB) and specific binding assays were performed to evaluate epidermal growth factor receptor (EGFR) expression and 89Zr-DFO-cetuximab uptake in FaDu cetuximab-resistant (FCR) and FaDu cetuximab-sensitive (FCS) cells. Positron emission tomography imaging and biodistribution were conducted in NU/NU nude mice implanted with FCR or FCS cells.
Results:
Cetuximab was successfully radiolabeled with 89Zr (≥95%). Binding assays performed in FCR and FCS cells showed significantly lower 89Zr-DFO-cetuximab uptake in FCR (p < 0.0001). WB suggests that the resistance mechanism is associated with EGFR downregulation (p = 0.038). This result is in agreement with the low uptake of 89Zr-DFO-cetuximab in FCR cells. Tumor uptake of 89Zr-DFO-cetuximab in FCR was significantly lower than FCS tumors (p = 0.0340).
Conclusions:
In this work, the authors showed that 89Zr-DFO-cetuximab is suitable for identification of EGFR downregulation in vitro and in vivo. This radiopharmaceutical may be useful for monitoring resistance in HNSCC patients during cetuximab therapy.
Get full access to this article
View all access options for this article.
References
1.
StromeSE, SausvilleEA, MannD. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist, 2007; 12:1084.
2.
LieberM. Antibody diversity: A link between switching and hypermutation. Curr Biol, 2000; 10:798.
3.
WrightBD, LapiSE. Designing the magic bullet? The advancement of immuno-PET into clinical use. J Nucl Med, 2013; 54:1171.
4.
McCarronPA, OlwillSA, MaroufWM, et al.Antibody conjugates and therapeutic strategies. Mol Interv, 2005; 5:368.
5.
HoebenBA, Molkenboer-KuenenJDM, OyenWJG, et al.Radiolabeled cetuximab: Dose optimization for epidermal growth factor recept or imaging in a head-and-neck squamous cell carcinoma model. Int J Cancer, 2011; 129:870.
6.
WiechecE, HanssonT, AlexanderssonL, et al.Hypoxia mediates differential response to anti-EGFR therapy in HNSCC cells. Int J Mol Sci, 2017; 18:943.
7.
LövqvistA, HummJL, SheikhA, et al.PET imaging of 86Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between 86Y and 111 in radiolabels. J Nucl Med, 2001; 42:1281–1287.
8.
LubnerSJ. Primary and acquired resistance to biologic therapies in gastrointestinal cancers. J Gastrointest Oncol, 2017; 3:499.
9.
MorgilloF, Della CorteCM, FasanoM, et al.Mechanisms of resistance to EGFR-targeted drugs: Lung cancer. ESMO Open, 2016; 1:1.
10.
BrandTM, LidaM, WheelerDL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther, 2011; 9:777.
11.
LievreA, BachetJB, Le CorreD, et al.KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res, 2006; 66:3992.
12.
Di FioreF, BlanchardF, CharbonnierF, et al.Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer, 2017; 96:1166.
13.
De RoockW, PiessevauxH, De ShutterJ, et al.KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol, 2008; 19:508.
14.
LoupakisF, PollinaL, StasiI, et al.PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol, 2009; 27:2622.
15.
BenvenutiS, Sartore-BianchiA, Di NicolantonioF, et al.Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to antiepidermal growth factor receptor antibody therapies. Cancer Res, 2007; 67:2643.
16.
SeverinGW, EngleJW, BarnhartTE, NicklesRJ. Zr-89 radiochemistry for positron emission tomography. Med Chem, 2012; 7:389–394.
17.
SchechterNR, ChechterNR, WendtRE, et al.Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. J Nucl Med, 2004; 45:1683.
18.
SchechterNR, YangDJ, AzhdariniaA, et al.Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody. Anticancer Drugs, 2003; 14:49.
19.
EvansHL, NguyenQ, CarrollLS, et al.A bioorthogonal 68 Ga-labeling strategy is alive rapid in imaging. Chem Commun, 2014; 50:9557.
20.
ZengD, GuoY, WhiteAG, et al.Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice. Mol Pharm, 2014; 11:3980.
21.
PingLW, MeyerLA, CaprettoDA, et al.Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm, 2008; 23:158.
22.
CaiW, ChenK, HeL, et al.Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging, 2007; 34:850.
23.
NiuG, LiZ, XieJ, et al.PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med, 2009; 50:1116.
24.
AndersonCJ, FerdaniR. Copper-64 radiopharmaceuticals for PET imaging of cancer: Advances in preclinical and clinical research. Cancer Biother Radiopharm, 2009; 4:379.
25.
VerelI, VisserGWM, BoermanOC, et al.Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm, 2014; 18:655.
26.
PentlowKS, GrahamMC, LambrechtRM, et al.Quantitative imaging of iodine-124 with PET. J Nucl Med, 1996; 37:1557.
27.
LeeFT, O'KeefeGJ, GanHK, et al.Immuno-PET quantitation of de2–de7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806. J Nucl Med, 2010; 51:967.
28.
ChengC, HoAS. SPECT imaging evaluation of 111indium-chelated cetuximab for diagnosing EGFR-positive tumor in a HCT15-induced colorectal xenograft. Gastroenterology, 2017; 152:551.
29.
ShihYH, PengCL, LeeSY, et al.111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma. Oncotarget, 2015; 6:16601.
30.
Van DijkLK, HoebenBAW, KaandersJHAM, et al.Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab′)2. J Nucl Med, 2013; 54:2118.
31.
MisriR, SaatchiK, IsriR, et al.Evaluation of (111)In labeled antibodies for SPECT imaging of mesothelin expressing tumors. Nucl Med Biol, 2011; 38:885.
32.
HuhtalaT, LaakkonenP, SallinenH, et al.In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies. Nucl Med Biol, 2010; 37:957.
33.
DivgiCR, WeltS, KrisM, et al.Phase I and imaging trial of indium-111 labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst, 1991; 83:97.
34.
ZhangY, HongH, CaiW. PET tracers based on Zirconium-89. Curr Radiopharm, 2011; 2:131.
35.
JauwYW, Menke-van der Houven van OordtCW, HoekstraOS, et al.Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: What can we learn from initial clinical trials?. Front Pharmacol, 2016; 7:131.
36.
PerkLR, VosjanMJ, VisserGW, et al.P-isothiocyanatobenzyl-desferrioxamine: A new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging, 2010; 37:250.
37.
Van LoonJ, EvenAJG, AertsHJW, et al.PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer. Radiother Oncol, 2016; 11:1016.
38.
EvenAJG, Hamming-VriezeO, van ElmptW, et al.Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: A theragnostic approach. Cancer Data, 2017; 83:1.
39.
VosjanMJWD, PerkLR, VisserGWM, et al.Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc, 2010; 5:739.
40.
van de WateringFCJ, RijpkemaM, PerkL, et al.Zirconium-89 labeled antibodies: A new tool for molecular imaging in cancer patients. Biomed Res Int, 2014; 14:1.
41.
NayakTK, BrechbielMW. Radioimmunoimaging with longer-lived positron-emitting radionuclides: Potentials and challenges. Bioconjug Chem, 2009; 5:825.
42.
VerelI, VisserGWM, BoellaardR, et al.89Zr immuno-PET: Comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med, 2003; 44:1271.
43.
DeriMA, ZeglisBM, FrancesconiLC, et al.PET imaging with 89Zr: From radiochemistry to the clinic. Nucl Med Biol, 2013; 40:3.
44.
AertsHJ, DuboisL, PerkL, et al.Disparity between in vivo EGFR expression and (89)Zr-labeled cetuximab uptake assessed with PET. J Nucl Med, 2009; 50:123.
45.
PerkLR, VisserGW, VosjanMJ, et al.89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody Cetuximab. J Nucl Med, 2005; 46:1898.
46.
Menke-VanCW, GootjesEC, HuismanMC, et al.89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget, 2015; 6:30384.
47.
MeijsWE, HerscheidJDM, HaismaHJ, et al.Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Appl Radiat Isot, 1992; 43:1443.
48.
WootenL, MadridE, SchweitzerGD, et al.Routine production of 89Zr using an automated module. Appl Sci, 2013; 3:593.
49.
van DongenGA, VisserGW, Lub-De HoogeMN, et al.Immuno-PET: A navigator in monoclonal antibody development and applications. Oncologist, 2007; 12:1379.
50.
NatarajanA, HabteF, GambhirSS. Development of a novel long-lived ImmunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model. Bioconjug Chem, 2012; 6:1221.
51.
MillenicDE, WongKJ, BaidooKE, et al.Cetuximab: Preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm, 2008; 23:619.
52.
QueernSL, AwedaTA, MassicanoAVF, et al.Production of Zr-89 using sputtered yttrium coin targets 89Zr using sputtered yttrium coin targets. Nucl Med Biol, 2017; 50:11.
53.
OliveiraJSR. Identificação de novos biomarcadores preditivos da resposta às terapias anti-EGFR em tumores sólidos: ênfase em tumores de cabeça e pescoço. (Doctoral dissertation, São Paulo, Brazil: Fundação Pio XII–Hospital de Câncer de Barretos). 2016.
54.
OkadaY, KimuraT, NakagawaT, et al.EGFR downregulation after anti-EGFR therapy predicts the antitumor effect in colorectal cancer. Mol Cancer Res, 2017; 16:1.
55.
TaoX, LuY, QiuS, et al.AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis. Cancer Lett, 2017; 408:33.
56.
SequistLV, WaltmanBA, Dias-SantagataD, et al.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 2011; 3:15.
57.
KaniK, GarriC, TiemannK, et al.JUN-mediated downregulation of EGFR signaling is associated with resistance to gefitinib in EGFR-mutant NSCLC cell lines. Mol Cancer Ther, 2017; 16:1645.
58.
ManoleS, RichardsEJ, MeyerAS. JNK pathway activation modulates acquired resistance to EGFR/HER2-targeted therapies. Cancer Res, 2016; 76:5219.
59.
BenedettoR. [89]Zr-Imuno-PET/[111] In-Imuno-SPECT: desenvolvimento radiofarmacêutico de agentes de imagem molecular para receptores EGF. (Doctoral dissertation, São Paulo, Brazil: Instituto de Pesquisas Energéticas e Nucleares). 2017.
60.
ChangAJ, De SilvaRA, LapiSE. Development and characterization of 89 Zr-labeled panitumumab for immuno–positron emission tomographic imaging of the epidermal growth factor receptor. Mol Imaging, 2013; 88:12117.
61.
EnglandCG. Preclinical pharmacokinetics and biodistribution studies of 89Zr-labeled pembrolizumab. J Nucl Med, 2017; 1:162.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
